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ABSTRACT: A cross-sectional study on HIV/AIDS was carried out in 108 outpatients from 
the university hospital of the Federal University of Mato Grosso do Sul, Campo Grande, 
Brazil, from July to December 2008, to investigate latent tuberculosis infection using the 
tuberculin skin test (TST). The prevalence of positive results was 13.9%. The CD4+ T cell 
count (p = 0.091) and the diagnosis time (p = 0.010) were statistically significant when 
compared with TST positivity. In the cohort of HIV/AIDS patients who had latent tuberculosis 
infection, the median diagnosis time was eight years. Undetectable viral load presented 
significant association (p = 0.046) with tuberculosis infection. The fact that numerous 
individuals with HIV/AIDS infection presented a negative reaction to the tuberculin skin test is 
probably related to alterations in the cellular immune response induced by HIV infection. The 
tuberculin test is a useful tool for the detection of latent tuberculosis infection and should be 
performed in all HIV/AIDS individuals at the time of the diagnosis and on a yearly basis, if 
negative. Both the early identification of the tuberculosis infection by the tuberculin skin test 
at the moment of immunological restoration and chemoprophylaxis in infected individuals are 
mechanisms to control HIV/AIDS and tuberculosis coinfection. 
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INTRODUCTION 
In 2006, the World Health Organization reported approximately 9.2 million cases of 
active tuberculosis with 1.7 million deaths worldwide per year. Among the 85,000 
cases of tuberculosis currently reported to the surveillance system in Brazil, nearly 
8% are coinfected with human immunodeficiency virus (HIV) (1-3). In Brazil, an 
average of 600,000 individuals is presently infected with HIV, which comprises one of 
the main risk factors for the progression from a latent tuberculosis infection to the 
active disease (1, 4-7). 
Persons recently infected with Mycobacterium tuberculosis have a 3 to 5% chance to 
develop the disease in the first two years and 5 to 15% during their lifetime (8). Most 
infected people remain healthy with a latent infection, demanding several immune 
mechanisms to prevent the disease progression (3, 9, 10). Tuberculosis cases result 
from the evolution of a latent reactivated focus or from a recent exogenous infection. 
Latent infection affects one third of the world population and the possibility of a latent 
reactivation focus in HIV-infected people, without intervention, may reach 10% every 
year (11, 12). Tuberculosis lies among the major causes of opportunistic diseases in 
HIV-infected patients, leading to high lethality (1, 4, 9, 13).  
The identification of latent tuberculosis infection makes possible the adoption of 
strategies to lower its morbidity and mortality rates in HIV/AIDS patients (4, 13-16). 
Even presenting limitations, the tuberculin skin test (TST) is the most commonly used 
infection-detection method and should be performed in all HIV-infected individuals at 
the time of diagnosis and annually, if the first result is negative (16). In asymptomatic 
HIV-positive patients an induration equal to or greater than 5 mm is a positive result 
(6, 8, 17). After a positive diagnosis, the patients should receive isoniazid 
chemoprophylaxis. The risk of reactivation of latent tuberculosis is believed to 
increase up to 100-fold when compared with HIV negative individuals, whereas the 
development of the active disease in the HIV/AIDS population may have an 
incidence of 1.7 to 7.9 per 100 persons per year (15, 18). 
The objective of the present study was to investigate latent tuberculosis infection 
using the tuberculin skin test (TST) in patients assisted at the university hospital in 
Campo Grande, Mato Grosso do Sul, Brazil, to compose the latent tuberculosis 
scenario in the midwest of Brazil. 
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PATIENTS AND METHODS 
Patients 
This is a cross-section descriptive study with quantitative approach. The HIV/AIDS 
population was selected from the Day-Care Hospital Prof. Esterina Corsini, at the 
Federal University of Mato Grosso do Sul (UFMS), Campo Grande, Brazil, in 2008. 
The sample size was calculated considering the prevalence of tuberculosis infection 
estimated in 15% (±6%), based on studies carried out with the HIV/AIDS population; 
significance level 5% (19-20). Thus, the minimal sample size to meet the aim of this 
study was 108 adult patients, a non-probabilistic sample of HIV/AIDS patients treated 
during June through December, 2008. 
 
Ethical Aspects 
The project was approved by the Ethical Committee of UFMS (protocol 1060). All 
volunteers signed a document of informed consent.  
 
Data Collection 
All participants were asked to answer a questionnaire on sociodemographic variables 
(age, gender and formal education level), childhood BCG (bacille Calmette-Guèrin) 
vaccination and social habits (alcohol and tobacco consumption). Information about 
the period of HIV/AIDS diagnosis and highly active antiretroviral treatment (HAART) 
was provided by medical records. Since CD4+ T and CD8+ T cell counts and HIV 
load are routinely performed as part of the clinical follow-up of all HIV/AIDS patients 
in Brazil, those results were obtained from the medical records, as close as possible 
to the TST time. The viral load test was performed by the Central Public Health 
Laboratory in Campo Grande, MS, using a b-DNA technique (Versant HIV-1 RNA 3.0 
Assay®, Siemens, USA) with the detection level ranging from 50 to 500,000 
copies/mL. The tuberculin skin test utilized a 2 UT (0.04 μg) purified protein 
derivative, (PPD), RT 23 (recent tuberculin), from the Statens Serum Institut 
(Denmark). An amount of 0.1 mL of this PPD is equivalent to 5 UT of other PPD-S 
used in some countries. The PPD was provided by the Hélio Fraga Filho Reference 
Center of the Brazilian Ministry of Health. A 0.1-mL dose of PPD was subcutaneously 
injected into the anterior side of the left forearm, forming a papule with well-defined 
borders (8). The induration was measured after 48 to 72 hours and results of at least 
5 mm were considered positive.  
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Statistical Analysis 
Chi-square (χ2) test was employed to evaluate the relation between latent 
tuberculosis infection and sociodemographic and clinical variables. Continuous 
variables (CD4+ T /CD8 +T cell counts and viral load) were examined by the median 
test. Stata® version 9 software (StataCorp LP, USA) was used for the statistical 
analysis. 
 
RESULTS 
Of the 492 HIV/AIDS patients clinically followed at the Day-Care Hospital Prof. 
Esterina Corsini, 108 were consecutively included from June to December 2008. 
Among the studied individuals, 53.70% (58) were females; 76.85% (83) were aged 
between 20 and 49 years, and in 62.96% (66) the formal education level ranged from 
0 to 10 years of schooling.  
Latent tuberculosis infection was identified in 13.9% of the HIV/AIDS patients, of 
whom 66.76% (10) were female and 73.3% were aged between 20 and 49 years. 
There was no statistical difference between the TST-positive HIV/AIDS patients and 
the TST-negative persons regarding sex, age, schooling, familiar income, smoking 
habit and alcohol abuse (screened through the CAGE questionnaire) as shown in 
Table 1.  
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Table 1. Sociodemographic characteristics and results of the tuberculin skin test of 
HIV/AIDS patients in Campo Grande, Mato Grosso do Sul state, Brazil, 2008 
Tuberculin skin test 
Positive Negative Total Sociodemographic characteristics 
n % n % n % 
p-value* OR (95% CI) 
Gender 
Male 5 33.33 45 48.39 50 46.30 1.000 
Female 10 66.67 48 51.61 58 53.70 
0.278 1.875 
(0.588-
5.979) 
Age group (years) 
20 to 49  11 73.33 72 77.42 83 76.85 1.000 
50 or more 4 26.67 21 22.58 25 23.15 
0.746ª 1.247 
(0.357-
4.351) 
Schooling (years) 
0 to 6 6 40.00 34 36.56 40 37.04 1.000 
7 or more  9 60.00 59 63.44 68 62.96 
0.798 1.400 
(0.368-
5.328) 
Smoking 
Never smoked 5 33.33 40 43.01 45 41.67 1.000 
Smoker/ex-smoker 10 66.67 53 56.99 63 58.33 
0.481 1.509 
(0.474-
4.802) 
CAGE 
No 10 83.33 48 82.76 58 82.86 1.000 
Yes 2 16.67 10 17.24 12 17.14 
0.999ª 0.960 
(0.180-
5.131) 
    
Positive Negative 
n Median IQR n Median
p-value** 
Per capita income (in R$) 
15 400 240; 750 89 333 
IQR 200; 
500 0.402 
* Pearson's chi-square test (ªFisher's exact test was used when the sample size was less than five). 
** Median test. 
Note: CAGE is an acronym for “Cut-down, Annoyed by criticism, Guilty and Eye-opener” 
questionnaire. 
 
The scar of BCG vaccination in childhood did not show statistical difference among 
TST-positive patients. Information about CD4+ T and CD8+ T cell counts was 
collected from all patients through their clinical records. In relation to other clinical 
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variables, CD4+ T cell count was significantly associated, at 10% level, with positive 
tuberculin test. In the negative tuberculin reaction group, the median value of CD4+ T 
cells was 390 cells/mm3, whereas in the TST positive group this count (average) was 
626 cells/mm3 (p-value = 0.091). It was also observed that among persons who 
reacted negatively, the median value of CD8+ T was higher than among those with 
positive TST (p-value = 0.026) and about twice as high as CD4+ T in the same group 
(Table 2).  
The diagnosis time showed to be considerably associated with TST positivity (p-
value = 0.01), with a median diagnosis time of eight years, whereas among TST-
negative patients, this period was four years (Table 2).  
The group of TST positive individuals in use of antiretroviral therapy did not present 
any statistical difference. Eighty-two and 41% HIV/AIDS patients were under highly 
active antiretroviral treatment. 
The viral load revealed a significant association (p-value = 0.046) when compared 
with the TST-positivity variable. A higher level of viral load was observed in TST-
negative individuals. In those who reacted positively, 80% (12/15) had undetectable 
viral RNA load (log ≤ 50 copies/mL), as displayed in Table 2, represented by the 
value 49.  
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Table 2. Clinical characteristics and tuberculin skin test among HIV/AIDS patients in 
Campo Grande, Mato Grosso do Sul state, Brazil, 2008 
Tuberculin skin test 
Positive Negative Total Clinical characteristics 
n % n % n % 
p-value* Odds ratio (OR)
BCG scar   
Yes 9 60.00 59 68.60 68 67.33 0.686 (0.220-2.140) 
No 6 40.00 27 31.40 33 32.67 
0.512 
1.000 
HAART  
Yes 13 86.67 76 81.72 89 82.41 1.454 (0.297-7.114) 
No 2 13.33 17 18.28 19 17.59 
0.999ª 
1.000 
Positive Negative 
n Median IQR n Median IQR 
p-value** 
CD4+ T cell count 
15 626 408; 977 93 390 251; 627.5 0.091 
CD8+ T cell count 15 763 596; 961 93 985 676.5;1227.5 0.026 
Viral load 15 49 49; 49 93 118 49; 9757.5 0.046 
Diagnosis time 
(years) 15 8 5; 11 92 4 1; 7 0.01 
* Pearson's chi-square test (ªFisher's exact test was used when the sample size was less than five). 
** Median test. 
 
DISCUSSION 
The prevalence of tuberculosis infection in Latin America is well documented and 
affects about 30% of the general population (13). In Europe and North America, 
although the prevalence of tuberculosis is lower, the reemergence of this disease has 
been well described, due to HIV/AIDS pandemics afflicting especially immigrants 
from Latin American countries and vulnerable populations (refugees, healthcare 
professionals, inmates and drugs addicts), who are more exposed to tuberculosis 
infection and disease (4, 21-25). Brazilian studies indicate a 20 to 50% prevalence of 
tuberculosis infection in susceptible persons such as healthcare professionals (25). 
The increase of tuberculosis and HIV/AIDS coinfection rates has given rise to serious 
implications for tuberculosis control programs due to the augmentation of cases and 
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elevated mortality rates in the coinfected population (13, 24). Several studies carried 
out in Latin American countries demonstrated that tuberculosis infection rates in 
HIV/AIDS population range from 0 to 25% (15, 20, 22, 26, 27). The present study 
found a 13.9% prevalence of tuberculosis infection in the HIV/AIDS population. 
The connection between the number of lymphocytes CD4+ T per cubic millimeter and 
the skin response to PPD remains unclear in the literature (16, 28). In the current 
study, no significant association between tuberculin positive individuals and CD4+T 
lymphocyte count was found. In the population who tested negative for tuberculin, the 
median value of CD4+ T cells showed to be significantly lower, as previously 
reported by other researchers (16, 20).  
Several studies reported that most HIV-infected individuals do not respond to the skin 
test with PPD, thus showing a statistical relation with a low CD4+T cell count (20). On 
the other hand, other works did not find any connection between TST positivity and 
induration higher than 5 mm or higher absolute counting of CD4+T cells (16). 
Moreover, anergy is soundly related to low CD4+T cell count (20). Some authors 
found 10 to 80% anergy in HIV/AIDS populations (20, 26). 
In the current study, it is worth noting that any participant with positive tuberculin test 
had CD4+T cell count lower than 200/mm3. In the literature, low CD4+T cell count is 
associated with negative tuberculin test (20, 26, 27). 
The prevalence of tuberculosis infection in the group of patients with CD4+T count 
equal to or greater than 350 cells/mm3 appears to be closest to reality, as individuals 
with CD4+T count equal to or less than 350/mm3 may have presented negative 
tuberculin test due to anergy (16). 
Likewise, the median value of CD8+ T was about twice greater than that of CD4+T in 
the group of negative individuals. CD4+ T and the components of this cell population 
in the lung, when infected by HIV, have their cellular activities damaged, increasing 
the vulnerability to opportunistic infections such as tuberculosis. CD8+T cells 
participate in the immune response against tuberculosis bacillus and animal models 
demonstrate the susceptibility to M. tuberculosis infection in this cell subpopulation. 
These cells are involved in the activation of macrophages and are sources of γ-
interferon and cytokines (20). 
The viral load comprises an important clinical marker in the progression of HIV and, 
in this study, showed to be associated with tuberculosis infection. The group of TST 
positive individuals had undetectable viral load (cutoff at 50 HIV-1 RNA copies/mL). 
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Elevated viral replication and increased viral load are known to be associated with 
accelerated deterioration of the immune system and drop of CD4+ T cell count  (24).  
Likewise, a longer diagnosis time may be associated with TST positivity due to 
extended periods of clinical follow-up and monitoring. Probably, the use of 
antiretroviral drugs in these patients reestablishes the preexisting hypersensitivity to 
the immunological memory to tuberculosis. This means that undetected individuals or 
those who previously tested negative for TST, in the absence of a new infection, 
present immunological recall to a preexisting TB hypersensitivity.  
Antiretroviral therapy is an important tool in the control of latent tuberculosis infection. 
Clinical and therapeutic follow-up of HIV/AIDS individuals provides protection factors 
against the development of tuberculosis, which are described as one of main 
determinants of recovery and an indicator of survival, reduction of hospitalalization, 
improvement in the quality of life and decrease of latent infections (15, 22, 28-30). 
However, monitoring alone is not sufficient for the tuberculosis control; thus, isoniazid 
preventive therapy is highly recommended (15, 18). 
Since numerous patients affected by HIV/AIDS infection were non-reactive to TST, 
probably due to alterations in cellular immune response caused by the virus, it is 
possible that, during the investigation of the booster phenomenon, an increase in the 
identification rate of infected individuals is noticed (8, 23, 31, 32).  
Boosting of TST comprises a retesting in the absence of a new infection, an 
immunological recall of preexisting hypersensitivity to tuberculosis (33). In order to 
evaluate the booster phenomenon, all negative patients were invited to repeat the 
TST after a period of one to three weeks. The occurrence of the booster 
phenomenon was identified when the first TST showed an induration smaller than 10 
mm and the second TST presented an increase greater than 6 mm when compared 
with the first evaluation, with an induration of at least 10 mm (8). 
Tuberculin test is a useful method in the detection of tuberculosis infection and 
should be performed in all HIV/AIDS patients at the time of diagnosis and annually if 
they present negative response. In the first test, the evaluation of the booster effect 
may be useful.  
The early identification of tuberculosis infection by TST at the moment of 
immunological restoration in addition to the management of chemoprophylaxis in 
infected individuals comprise effective means for controlling the interaction between 
HIV/AIDS and tuberculosis. Other alternatives, including the investigation of booster 
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phenomenon and techniques such as interferon release assays (in vitro) are 
possibilities that may be further investigated in the diagnosis of latent infection (16). 
Healthcare services must overcome the operational difficulties and offer yearly 
tracing to these individuals.  
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